Re-evaluation of biologic therapies in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 22, Issue 3, 2010, Pages 273-277

  Bruce, Ian N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Belimumab; Biologic therapy; Clinical trials; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ABETIMUS; BELIMUMAB; CYCLOPHOSPHAMIDE; EPRATUZUMAB; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID;

DISEASE ACTIVITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; EVALUATION; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; OUTCOME ASSESSMENT (HEALTH CARE); TREATMENT OUTCOME;

EID: 77950275106     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3283374e78     Document Type: Review

References (27)

1. LeandroMJ, Cambridge G, Edwards JC, etal. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44:1542-1545.
2. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER. Arthritis Rheum 2008; 58:4029-4030.
3. Furie R, Looney RJ, Rovin B, etal. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum 2009; 60 (Suppl 1): S429.
4. Trial watch: BLYS-targeted antibody shows promise in phase III SLE trial. Nat Rev Drug Discov 2009; 8:688.
5. UCB Pharmaceuticals. UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE). www.ucb.com/media-room/newsdetail/?det=1337304. 2009.
6. Biomarin Phermaceuticals. Results of first interim efficacy analysis for Riquent phase 3 ASPEN Trial: continuation of the trial is futile. http://phx.corporate-ir.net/phoen ix.zhtml?c=1 06657p=irol-newsArticleID= 1255856high light=. 2009.
7. Merrill JT, Burgos-Vargas R, Westhovens R, etal. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Arthritis Rheum 2008; 58:4031-4032.
8. Reuters. Teva Pharm announces that the co's synthetic peptide, edratide (TV-4710), did not meet its primary endpoint in the PRELUDE trial. www.reu ters.com/article/inPlayBriefing/idUSIN20070919110056TEVA20070919. 2009.
9. Gilboe IM, Kvien TK, Husby G. Disease course in systemic lupus erythema tosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 2001; 28:266-274.
10. Nikpour M, Urowitz MB, Ibanez D, Gladman DD. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum 2009; 61:1152-1158.
11. Gladman DD, Urowitz MB, Rahman P, et al. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30:1955-1959.
12. Urowitz M, Gladman D, Ibanez D, et al. Damage due to glucocorticoids in a multicentre SLE inception cohort. Arthritis Rheum 2009; 60 (Suppl 1):S103.
13. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009; 61:482-487.
14. Reynolds JA, Toescu V, Yee CS, et al. Effects of rituximab on resistant SLE disease including lung involvement. Lupus 2009; 18:67-73.
15. Li EK, Tam LS, Zhu TY, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 2009; 48:892-898.
16. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18:767-776.
17. Wallace DJ, Stohl W, Furie RA, etal. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61:1168-1178.
18. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009; 61:1143-1151.
19. Human Genome Sciences. Human Genome Sciences and Glaxo Smith Kline announce positive results in second of two phase 3 trials of BENLYSTA in systemic lupus erythematosus. www.hgsi.com/latest/human-genome-sciences-and- glaxosmithkline-announce-positive-results-in-second-of-two-phase-3-trials-of- benlysta-in-systemic-lupus-erythema.html.
20. Petri M, Hobbs K, Gordon C, et al. Clinically meaningful improvements with epratuzumab (Anti-CD22 mAb targeting b-cells) in patients (Pts) with Moderate/Severe SLE flares: results from 2 randomized controlled trials. Arthritis Rheum 2008; 58:S571.
21. Alarcon-Segovia D, Tumlin JA, Furie RA, et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48:442-454.
22. Cardiel MH, Tumlin JA, Furie RA, et al. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008; 58:2470-2480.
23. Merrill JT, Mhatre M, Carthen F, etal. Mycophenolate mofetil (MMF) is effective for systemic lupus (sle) arthritis, final results of an organ-specific, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60 (Suppl 1):S97.
24. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index. J Rheumatol 2002; 29:288-291.
25. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86:447-458.
26. Yee CS, Farewell V, Isenberg DA, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) 2009; 48:691-695.
27. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741-745.